Parkinson's in the Media

More Evidence Ties Diabetes to Parkinson's Risk
People with diabetes may have a heightened risk of developing Parkinson's disease, especially at a relatively young age, a new study finds.  Published in the journal Diabetes Care, the study adds to recent research linking diabetes to Parkinson's disease.  More…

Eye Tremors May Aid Early Diagnosis of Parkinson's: Study
US News & World Report
Persistent eye tremors appear to be common in people with Parkinson's disease.  The tremors affect a person's eye stability while tracking moving objects, a new study finds.  The findings suggest that testing eyeball movement -- "oculomotor testing" -- could help provide an early marker for diagnosing the nervous-system disease, the researchers said.  More…

The Future of Stem Cells 
AARP (3-part video series; Amy Comstock Rick featured in 3rd video)
On this episode of “Inside E Street,” Lark McCarthy is joined by Mahendra Rao, director of the Center for Regenerative Medicine at the National Institutes of Health, for a special talk on the latest innovative findings related to stem cells.  David Prentice, of the Family Research Council, and Amy Comstock Rick, CEO of the Parkinson’s Action Network participate in a panel discussion on another type of cells – so-called iPS cells – and the future of adult stem cell research.  More…

Abbott Reports Positive Study Data for Parkinson's Disease Gel
The Wall Street Journal
Abbott Laboratories (ABT) reported positive results from a Phase 3 trial evaluating the company's gel treatment for advanced Parkinson's disease.  Abbott said the study found patients treated with its levodopa-carbidopa intestinal gel showed clinically meaningful and statistically significant improvement in "off" time -- or periods of poor mobility, slowness and stiffness--compared with the standard oral treatment.  The study also found an improvement in patients' "on" time -- or periods of good motor-symptom control -- without troublesome dyskinetic symptoms.  More…

Sanofi to Test Parkinson's Drug with Michael J. Fox Foundation
French drugmaker Sanofi said on Thursday it would collaborate with the Michael J. Fox Foundation to test an early- stage experimental treatment for Parkinson's disease.  Under the terms of the collaboration, MJFF will sponsor a phase I clinical trial to study the safety and tolerability of Sanofi's AVE8112, a drug that has shown promise in preclinical tests as a therapy for some of the psychiatric symptoms of the disease.  More…

Services Match Patients With Clinical Trials
The Wall Street Journal [Note: This article featured PAN Illinois Assistant State Director Claudia Garrido-Revilla]
A growing number of patient-advocacy groups are playing matchmaker, linking patients to researchers who need them for clinical trials.  The move comes as a persistent shortage of volunteers has slowed trials of new treatments for cancer and other diseases, which typically involve a patient receiving a drug or a placebo. People, including healthy volunteers, also are urgently needed for studies to contribute to the overall understanding of diseases including Parkinson's and Alzheimer's, experts say.  More…

Back to April 2012 Monthly Message